iSpecimen (ISPC) Stock Price, News & Analysis

Company Overview

iSpecimen, Inc. operates a digital marketplace designed to connect life sciences researchers with human biospecimens and related clinical information. Its platform helps researchers identify and request samples such as blood, tissue, and other biological materials from hospitals, laboratories, biobanks, and other healthcare or research organizations.

The company’s services support biospecimen sourcing, patient and donor matching, inventory discovery, order management, and sample logistics. iSpecimen serves pharmaceutical and biotechnology companies, diagnostic developers, academic institutions, and other organizations conducting biomedical research and developing new therapies and tests.

Founded in 2009, iSpecimen has focused on using software to streamline access to traditionally fragmented biospecimen inventories. Its marketplace is intended to support research across multiple disease areas and geographic regions, subject to the availability of participating providers and applicable regulatory and privacy requirements.

Key Stats

• Today's Range: $1.18 to $1.30
• 50-Day Range: $1.21 to $2.38
• 52-Week Range: $1.18 to $53.92
• Volume: 530,500 shs
• Average Volume: 1.43 million shs
• Market Capitalization: $3.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

iSpecimen Stock Analysis - MarketRank™

iSpecimen scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

iSpecimen has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

iSpecimen has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of iSpecimen is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of iSpecimen is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

iSpecimen has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.98% of the float of iSpecimen has been sold short.

Short Interest Ratio / Days to Cover

iSpecimen has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in iSpecimen has recently increased by 53.30%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

iSpecimen does not currently pay a dividend.

Dividend Growth

iSpecimen does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.26

News Sentiment

iSpecimen has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for iSpecimen this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for ISPC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added iSpecimen to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, iSpecimen insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.20% of the stock of iSpecimen is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

13.62% of the stock of iSpecimen is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/26/2026
• AGM 2026: 10/09/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:ISPC
• CIK: 1558569
• Web: ispecimen.com
• Phone: 781-301-6700
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($56.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.49 million
• Net Margins: -2,445.40%
• Pretax Margin: -2,445.61%
• Return on Equity: -524.39%
• Return on Assets: -140.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.82
• Quick Ratio: 0.82

Sales & Book Value

• Annual Sales: $1.93 million
• Price / Sales: 1.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.57 per share
• Price / Book: 0.09

Miscellaneous

• Outstanding Shares: 2,520,000
• Free Float: 2,212,000
• Market Cap: $3.18 million
• Optionable: Not Optionable
• Beta: 1.62